Fellowship - Award - 2016-2017 Pathogenesis and Treatment of Ebola-Associated Uveitis Rationale |
Nisha Acharya, MD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Eye Disease and Blindness |
|
|
Predicting and Improving Outcomes in Bacterial and Fungal Keratitis |
Nisha Acharya, MD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Eye Disease and Blindness |
|
|
Predicting and Improving Critical Outcomes for Bacterial Keratitis |
Nisha Acharya, MD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Eye Disease and Blindness |
|
|
Mycotic Ulcer Treatment Trial (MUTT) |
Nisha Acharya, MD |
Infectious Disease, Eye Disease and Blindness |
|
|
Leveraging mosquito antiviral immunity to detect viral infections: Towards a scalable field-based approach for predicting arbovirus epidemics |
Raul Andino-Pavlovsky, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
RNAi as an Intercellular Antiviral Defense Mechanism |
Raul Andino-Pavlovsky, PhD |
Infectious Disease, Genetics |
|
|
Cap Independent Translation of Dengue Virus |
Raul Andino-Pavlovsky, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Replication, Pathogenesis and Evolution of RNA Viruses, Including Dengue |
Raul Andino-Pavlovsky, PhD |
Infectious Disease, Neglected Tropical Diseases (NTDs) |
|
|
Virus population dynamics, genetic diversity and evolution |
Raul Andino-Pavlovsky, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Subcontract Work in Association with LLNL LDRD Project: COMP-08ERD036 |
Raul Andino-Pavlovsky, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
RAPID: Ebola virus population structure, genetic diversity and evolution |
Raul Andino-Pavlovsky, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Linking Virus Population Genetic Structure to Infectivity and Adaptation |
Raul Andino-Pavlovsky, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Quasispecies and drug resistance |
Raul Andino-Pavlovsky, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Mechansims of poliovirus replication |
Raul Andino-Pavlovsky, PhD |
Infectious Disease, Noncommunicable and/or Chronic Disease, Genetics |
|
|
Genetic Diversity as a Determinant of Viral Adaptation and Pathogenesis |
Raul Andino-Pavlovsky, PhD |
Infectious Disease, Immunology |
|
|
2013 NIH Workshop on Protein Homeostasis and Viral Infection |
Raul Andino-Pavlovsky, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance |
|
|
BSL3 upgrading for Live-attenuated poliovirus testing |
Raul Andino-Pavlovsky, PhD |
Infectious Disease, Immunology |
|
|
Selective AAK1 and GAK inhibitors for combating Dengue and other emerging viral infections |
Raul Andino-Pavlovsky, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Immunology |
|
|
EV71 intra-host evolution, attenuation and vaccine development |
Raul Andino-Pavlovsky, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Genetic Diversity as a Determinant of Viral Pathogenesis and Attenuation |
Raul Andino-Pavlovsky, PhD |
Infectious Disease, Genetics, Risk Reduction and Prevention |
|
|
INTERCEPT: Interfering and Co-evolving Prevention and Therapy |
Raul Andino-Pavlovsky, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Insect adaptive immunity |
Raul Andino-Pavlovsky, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
A Collaborative Approach to the Design of a Genetically-Stable Oral Polio Vaccine (OPV-2) |
Raul Andino-Pavlovsky, PhD |
Infectious Disease, Drug and Diagnostics Development |
|
|
2.1 Project Title ACTG: AIDS Clinical Trials Group |
Francesca Aweeka, PharmD |
Infectious Disease, HIV/AIDS, Tuberculosis |
|
|
Regulation of Virulence Traits in a Fungal Pathogen of Cancer Patients |
|
Zoonosis, Emerging Disease, and Drug Resistance, Occupational and Environmental Disease |
|
|
Regulatory Networks That Control Cell Morphology and Virulence in the Fungal Respiratory Pathogen Histoplasma capsulatum |
|
Infectious Disease |
|
|
Intervention to Decrease Risk for STDs and Unintended Pregnancies in Active Duty Military Women |
|
Sexually Transmitted Infections (STIs), Women's Health, Family Planning |
|
|
An Automated High Throughput Phenotypic Screen for Schistosomiasis Drug Discovery |
|
Infectious Disease, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
Exploring Statins As a Small Molecule Therapy for Treatment of Schistosomiasis |
|
Neglected Tropical Diseases (NTDs), Noncommunicable and/or Chronic Disease, Risk Reduction and Prevention |
|
|
A schistosome cysteine protease in Th response polarization |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
Identifying inhibitors of Parasitic Worm Activity |
|
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
A New Field Assay to Diagnose and Monitor Schistosomiasis |
|
Sexually Transmitted Infections (STIs), Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Schistosoma mansoni: Identification and Validation of New Targets for Therapy Using a siRNA Screen |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
Biology of Infectious Diseases Training Program |
Henry Chambers, MD |
Infectious Disease, Training and Capacity Building |
|
|
Applied Research on Antimicrobioal Resistance: Molecular Epidemiology of Community Methicillin-resistant Staphylococcus aureus (MRSA) |
Henry Chambers, MD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Protocol Development for a Phase 2 Study Evaluating the Safety and Feasibility of Ceftobiprole Compared to Conventional Therapy in the Treatment of Subjects w/ Staphylococcus aureus Bacteremia |
Henry Chambers, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Novel Mechanisms of Beta-lactam Resistance in Staph Aureus, Continuation A120553 |
Henry Chambers, MD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Ceftobiprole vs. Daptomycin and Linezolid for Treatment of Experimental Staph. aureus Endocarditis in Rabbits |
Henry Chambers, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Biology of Infectious Diseases Training Program |
Henry Chambers, MD |
Infectious Disease, Residencies, Fellowships, and Postdoctoral Training |
|
|
Phase 2 Study, Safety of and Rate of Bacterial Clearance of Ceftobiprole Compared to Conventional Therapy in the Treatment of Subjects w/ Staphylococcus aureus Bacteremia |
Henry Chambers, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Multidrug-Resistant CA-MRSA Infections Among HIV+ Persons: CA AIDS Grant ID07-REI-129 |
Henry Chambers, MD |
Infectious Disease, Sexually Transmitted Infections (STIs), Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Epidemiology and Surveillance |
|
|
A Clinical Trial for Uncomplicated Skin Infections in Areas of Epidemic Community-Associated Methicillin-Resistant Staphylococcus aureus (MRSA) |
Henry Chambers, MD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Opportunistic Infection |
|
|
Efficacy Evaluation and Safety of Single-dose IV Oritavancin vs. IV Vancomycin for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infection (SOLO I) |
Henry Chambers, MD |
Infectious Disease |
|
|
Antibacterial Resistance Leadership Group (ARIG) |
Henry Chambers, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Systematic Reviews and Guideline Development |
|
|
A Phase 2, Randomized, Open-Labeled Study on the Safety of and Rate of Bacterial Clearance of Ceftobiprole Compared to Conventional Therapy in the Treatment of Subjects w/ Staphylococcus aureus Bacteremia |
Henry Chambers, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Proposed Experiments to Study Emergence of Antimicrobial Resistance in Methicillin- Resistant Strains of Staphylococcus aureus |
Henry Chambers, MD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Tetrezolid vs. Daptomycin and Vancomycin for Treatment of Experimental Staphylococcus aureus |
Henry Chambers, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Study for Sample Acquisition for Patients Diagnosed with S. aureus Bacteremia |
Henry Chambers, MD |
Infectious Disease, Drug and Diagnostics Development, Epidemiology and Surveillance |
|
|
Novel Mechanisms of Beta-Lactam Resistance in Staph aureus |
Henry Chambers, MD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
UZ-UCSF CTU Spilhaus Clinical Research Site HPTN 076 2nd Protocol Funding |
Zvavahera Chirenje, MD, FRCOG |
Infectious Disease, HIV/AIDS, Drug and Diagnostics Development, Women's Health, Training International Scholars and Clinicians, Patient and Peer Education |
|
|
UZ-UCSF Clinical Trials Unit |
Zvavahera Chirenje, MD, FRCOG |
Sexually Transmitted Infections (STIs), HIV/AIDS, Women's Health |
|
|
UZ-UCSF Clinical Trials Unit |
Zvavahera Chirenje, MD, FRCOG |
Infectious Disease, HIV/AIDS, Pediatrics, Newborn and Infant Health, Risk Reduction and Prevention |
|
|
Whole Blood/Serum Samples from Patients with Hepatitis |
Charles Chiu, MD, PhD |
Infectious Disease, Drug and Diagnostics Development |
|
|
Development of the infant gastrointestinal virome and shedding of oral polio and rotavirus vaccines in Bangladeshi and US infants |
Charles Chiu, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development, Newborn and Infant Health |
|
|
Real-Time Unbiased Pathogen Detection in Febrile Illnesses by Nanopore Sequencing |
Charles Chiu, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Viral Discovery in Human and Animal Samples |
Charles Chiu, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
CCD Study- RNA Sequencing |
Charles Chiu, MD, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Pan-Genomic Approaches for Comprehensive Blood Screening of Novel or Emerging Infectious Agents |
Charles Chiu, MD, PhD |
Infectious Disease |
|
|
Using Pan-Pathogen Microarrays and Deep Sequencing to Search for the Cause of Southern Tick-Associated Rash Illness (STARI) |
Charles Chiu, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Metabiota - Viral Surveillance for the PREDICT Program 20150410 |
Charles Chiu, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
Pathogen discovery and epidemiology in tick vectors associated with Lyme-like diseases |
Charles Chiu, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
A Combined Pathogen-Host Sequencing Assay for Diagnosis of Lyme and Other Tickborne Infections |
Charles Chiu, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Clin 0003 Identification and Characterization of a Putative Novel Poxvirus in the DRC |
Charles Chiu, MD, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Pathogen characterization and discovery by deep sequencing of two major vectors associated with Lyme disease and other tickborne infections |
Charles Chiu, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Broad Detection of Infectious Agents in Blood by Microarrays and Deep Sequencing |
Charles Chiu, MD, PhD |
Infectious Disease, Drug and Diagnostics Development |
|
|
Identification of Signaling Pathways Associated with Lyme Disease |
Charles Chiu, MD, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Serological prevalence of viral hemorrhagic fevers in Equatorial Africa |
Charles Chiu, MD, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Multiplexed Viral and Cytokine Response Assays Using NanoString Technology |
Charles Chiu, MD, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Comprehensive Diagnostics for Viral Encephalitis/Meningitis |
Charles Chiu, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Pathogen Discovery in PREDICT Human and Wildlife samples to Detect and Identify Viruses Present, Both Known and Novel |
Charles Chiu, MD, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Comprehensive Diagnostics for Viral Encephalitis/Meningitis |
Charles Chiu, MD, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Simcere Surpi eval project |
Charles Chiu, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Real-Time Detection of Bloodborne Pathogens by Unbiased Nanopore Sequencing 20150506 |
Charles Chiu, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
To Discover and Characterize Novel Viruses in Cancer |
Charles Chiu, MD, PhD |
Infectious Disease, Cancer/Oncology |
|
|
A Rapid Pan-Viral Microarray Diagnostic for Category A-C Biodefense Pathogens |
Charles Chiu, MD, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Clin 0004 Characterization of Viral Hemorrhagic Fevers of Unknown Origin |
Charles Chiu, MD, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
The Medical Consequences of Different Types of Heroin |
Daniel Ciccarone, MD, MPH |
Infectious Disease, HIV/AIDS, Substance Abuse |
|
|
HepC/HIV website |
Susan Coffey, MD |
HIV/AIDS, Infectious Disease |
|
|
HIV-HEP C Website Maintenance Services |
Susan Coffey, MD |
Infectious Disease, HIV/AIDS, Patient and Peer Education |
|
|
Mycoplasma Genitalium in the Female Genital Tract |
Craig Cohen, MD, MPH |
Infectious Disease, Sexually Transmitted Infections (STIs), Women's Health |
|
|
Preclinical Development of MucoCept |
Craig Cohen, MD, MPH |
Sexually Transmitted Infections (STIs), Women's Health |
|
|
Phase 2 placebo-controlled randomized trial of LACTIN-V (Lactobacillus crispatus CTV-05) among women at high risk of HIV acquisition in Durban, South Africa |
Craig Cohen, MD, MPH |
HIV/AIDS, Sexually Transmitted Infections (STIs), Women's Health |
|
|
University of California Global Health Institute Program for Fellows and Scholars |
Craig Cohen, MD, MPH |
Infectious Disease, HIV/AIDS, Tuberculosis, Malaria, Surgery and Anesthesia, Cancer/Oncology, Chronic Respiratory Disease, Diabetes, Occupational and Environmental Disease, Eye Disease and Blindness, Oral Health, Dementia and Cognitive Impairment, Trauma and PTSD, Women's Health, Pediatrics, Policy and Standards of Care, Epidemiology and Surveillance |
|
|
FACES Patient Care fund for research at Kenya |
Craig Cohen, MD, MPH |
HIV/AIDS, Infectious Disease, Sexually Transmitted Infections (STIs), Cancer/Oncology, Diet, Exercise, and Obesity, Women's Health, Labor and Delivery, Family Planning, Pediatrics, Newborn and Infant Health, Adolescent Health, Health Economics and Effectiveness, Access or Barriers to Care, Stigma and Discrimination, Training and Capacity Building, Training International Scholars and Clinicians |
|
|
Satellite Symposium at Microbicides 2010 on Bacterial Therapeutics |
Craig Cohen, MD, MPH |
Sexually Transmitted Infections (STIs), HIV/AIDS, Women's Health |
|
|
Chlamydia and Gonococcal Infection: Immunobiology in the Female Reproductive Tract |
Craig Cohen, MD, MPH |
Infectious Disease, Sexually Transmitted Infections (STIs), Women's Health |
|
|
University of California Global Health Institute Program for Fellows and Scholars |
Craig Cohen, MD, MPH |
Sexually Transmitted Infections (STIs), Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), HIV/AIDS, Opportunistic Infection, Tuberculosis, Malaria, Noncommunicable and/or Chronic Disease, Surgery and Anesthesia, Cancer/Oncology, Cardiovascular Disease, Chronic Respiratory Disease, Diabetes, Occupational and Environmental Disease, Diet, Exercise, and Obesity, Malnutrition, Micronutrients, Food Insecurity, Eye Disease and Blindness, Oral Health, Drug and Diagnostics Development, Immunology, Genetics, Pharmacology and Drug Treatment, Neurology and Mental Health, Dementia and Cognitive Impairment, Trauma and PTSD, Women's Health, Aging, Labor and Delivery, Family Planning, Pediatrics, Newborn and Infant Health, Adolescent Health, Health Economics and Effectiveness, Access or Barriers to Care, Immigration and Migration, Stigma and Discrimination, Smoking and Tobacco, Policy and Standards of Care, Systematic Reviews and Guideline Development, Epidemiology and Surveillance, Triangulation, Global Strategic Information, Implementation and Behavioral Science, Engagement in Care, Substance Abuse, Treatment Adherence, Health Systems Strengthening, Risk Reduction and Prevention, Residencies, Fellowships, and Postdoctoral Training |
|
|
Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 |
Craig Cohen, MD, MPH |
Sexually Transmitted Infections (STIs), Women's Health |
|
|
Investigation of the Natural History of Human Papillomavirus (HPV) DNA and Cervical Neoplasia in a Cohort of Sex Workers in Kenya |
Craig Cohen, MD, MPH |
Infectious Disease, Sexually Transmitted Infections (STIs), Women's Health |
|
|
Secretion of Virulence Factors by Mycobacterium tuberculosis |
|
Infectious Disease, HIV/AIDS, Tuberculosis, Genetics |
|
|
Targeting host autophagy for treating Mtb infections and synergizing with antibiotics in vivo |
|
Zoonosis, Emerging Disease, and Drug Resistance, Tuberculosis, Pharmacology and Drug Treatment |
|
|
Host-Directed Strategies to Create Synergistic Antibacterial Therapies |
|
Zoonosis, Emerging Disease, and Drug Resistance, Tuberculosis, Drug and Diagnostics Development, Immunology |
|
|
Enfuvirtide Intensification for Multi-Drug Resistant HIV |
Steven Deeks, MD |
Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Novel Anti-Malarials by Combinatorial Pharmacogenomics |
Joseph Derisi, PhD |
Infectious Disease, Malaria, Drug and Diagnostics Development |
|
|
The Microbiome, Virome and Host Response in Ventilator Associated Pneumonia |
Joseph Derisi, PhD |
Infectious Disease, Opportunistic Infection |
|
|
Core B: Intracellular Pathogens and Innate Immunity |
Joseph Derisi, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Immunology |
|
|
Genomic Technology Development and Infectious Diseases |
Joseph Derisi, PhD |
Infectious Disease |
|
|
Detection and Discovery of Viral Pathogens Associated with Dengue-like Symptoms in Nicaragua |
Joseph Derisi, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Epidemiology and Surveillance |
|
|
Framework to Address Drug Resistant Infections and Global Health |
Joseph Derisi, PhD |
Infectious Disease |
|
|
UCDRD Whitepaper: Viral Pathogens |
Joseph Derisi, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Microbial Pathogenesis and Host Defense |
Joanne Engel, MD, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Training International Scholars and Clinicians |
|
|
New approaches to study Pseudomonas-host interactions |
Joanne Engel, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Novel approaches to identify host genes required for Chlamydia pathogenesis |
Joanne Engel, MD, PhD |
Infectious Disease, Sexually Transmitted Infections (STIs), Drug and Diagnostics Development |
|
|
High throughput proteomics to dissect Chlamydia-host cell interactions |
Joanne Engel, MD, PhD |
Infectious Disease, Sexually Transmitted Infections (STIs), Genetics, Risk Reduction and Prevention |
|
|
Preventing Fucose-Dependent Binding of Aspergillus and Pseudomonas to Lung Mucin |
|
Infectious Disease, Chronic Respiratory Disease, Genetics |
|
|
Utility of Contact Investigation of Drug Susceptible and Resistant Tuberculosis in Tanzania |
Elizabeth Fair, PhD, MPH |
Zoonosis, Emerging Disease, and Drug Resistance, Tuberculosis, Epidemiology and Surveillance |
|
|
Detection of Viral Pathogens in Indian Patients Who Have Suspected Viral Encephalitis |
|
Infectious Disease |
|
|
Predicting Progression of Human Prion Disease |
Michael Geschwind, MD, PhD |
Infectious Disease, Neurology and Mental Health |
|
|
Early Diagnosis of Human Prion Disease |
Michael Geschwind, MD, PhD |
Infectious Disease, Drug and Diagnostics Development |
|
|
AIDS Education and Training Center, National Clinician Consultation Center |
Ronald Goldschmidt, MD |
Infectious Disease, Sexually Transmitted Infections (STIs), HIV/AIDS, Training International Scholars and Clinicians, Residencies, Fellowships, and Postdoctoral Training, UCSF Professional Education, Patient and Peer Education |
|
|
Phase 1 Train of Na-APR-w and Na-GST-1 Hookworm Vaccine in Brazilian Adults |
Bryan Greenhouse, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Mentoring translational scientists in international infectious disease research |
Bryan Greenhouse, MD |
Infectious Disease, Malaria, Residencies, Fellowships, and Postdoctoral Training |
|
|
Acute Hepatitis C Infection in Young Injectors (incoming sub) |
Judith Hahn, PhD, MD |
Infectious Disease, Substance Abuse |
|
|
Dynamic Modeling of the Hepatitis C Epidemic in Injection Drug Users |
Judith Hahn, PhD, MD |
Sexually Transmitted Infections (STIs), Epidemiology and Surveillance |
|
|
Sustainable East Africa Research in Community Health (SEARCH) |
Diane Havlir, MD |
HIV/AIDS, Infectious Disease, Noncommunicable and/or Chronic Disease, Health Economics and Effectiveness, Access or Barriers to Care |
|
|
ADS-TCAD-P0206: TCAD Oral for Treatment of Influenza A |
Diane Havlir, MD |
Infectious Disease, HIV/AIDS, Opportunistic Infection, Pharmacology and Drug Treatment |
|
|
PCP OPW Specimens/Uganda Project Support |
Laurence Huang, MD |
Infectious Disease, HIV/AIDS, Opportunistic Infection |
|
|
AIDS Clinical Trials Network (ACTG) - Transformative Science Group Vice Chair) |
Peter Hunt, MD |
Infectious Disease, HIV/AIDS, Tuberculosis |
|
|
HIV Emergence of Drug Resistance |
|
Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Sanitation, Water, and Instruction in Face-washing for Trachoma (SWIFT) |
Jeremy Keenan, MD, MPH |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Eye Disease and Blindness |
|
|
The Impact of WASH on Re-infection with STH |
Jeremy Keenan, MD, MPH |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Epidemiology and Surveillance, Risk Reduction and Prevention |
|
|
Hcv-Induced Alterations in Glucose Metabolism |
Mandana Khalili, MD |
Infectious Disease, Diabetes |
|
|
Hepatocellular Carcinoma Screening Practices in Hepatitis B (HBV) Infected Asian Americans |
Mandana Khalili, MD |
Infectious Disease |
|
|
Pegylated Interferon Lambda w/wo Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 |
Mandana Khalili, MD |
Sexually Transmitted Infections (STIs) |
|
|
Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B |
Mandana Khalili, MD |
Infectious Disease |
|
|
Host and Viral Predictors of Prediabetes in at-risk Latinos with Chronic Hepatitis C (HCV) |
Mandana Khalili, MD |
Infectious Disease, Diabetes |
|
|
Mentoring Multidisciplinary Patient-Oriented Research in Viral Hepatitis |
Mandana Khalili, MD |
Infectious Disease, Residencies, Fellowships, and Postdoctoral Training |
|
|
GS-US-248-0122: A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection |
Mandana Khalili, MD |
Infectious Disease |
|
|
Screening and Management of Chronic Hepatitis B Virus Infection: A Survey of San Francisco Health Care Providers |
Mandana Khalili, MD |
Infectious Disease |
|
|
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults with Compensated Chronic Hepatitis B |
Mandana Khalili, MD |
Infectious Disease |
|
|
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults with Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection |
Mandana Khalili, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with Chronic Hepatitis B who are Virologically Suppressed |
Mandana Khalili, MD |
Infectious Disease |
|
|
GS-US-367-1172: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting |
Mandana Khalili, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects with Genotype 1, 4, 5 and 6 Chronic HCV Infection Who are on Dialysis for End Stage Renal Disease |
Mandana Khalili, MD |
Infectious Disease |
|
|
AI452-020-0092: Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-naïve or Re |
Mandana Khalili, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Mentoring Multidisciplinary Patient-Oriented Research in Viral Hepatitis |
Mandana Khalili, MD |
Sexually Transmitted Infections (STIs) |
|
|
Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepatitis B Virus |
Mandana Khalili, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
HBV/HIV Co-Infection Research Network |
Mandana Khalili, MD |
Sexually Transmitted Infections (STIs), HIV/AIDS |
|
|
Insulin Resistance in HCV Infection |
Mandana Khalili, MD |
Sexually Transmitted Infections (STIs) |
|
|
Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepatitis B Virus |
Mandana Khalili, MD |
Infectious Disease |
|
|
PEGASYS plus Copegus in treatment-naïve Latino patients with chronic hepatitis C-genotype 1, as compared to treatment-naïve non-Latino White patients with chronic hepatitis C-genotype 1 |
Mandana Khalili, MD |
Infectious Disease |
|
|
Village Integrated Eye Workers Trial |
Thomas Lietman, MD |
Infectious Disease, Eye Disease and Blindness, Risk Reduction and Prevention |
|
|
Trachoma control in Africa through mass antibiotic administration, and corneal ulcer prevention and treatment in South Asia |
Thomas Lietman, MD |
Infectious Disease, Eye Disease and Blindness |
|
|
P-S RPB - Assessing Corneal Ulcer Prevention with a Community-Randomized Trial |
Thomas Lietman, MD |
Neglected Tropical Diseases (NTDs), Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
NTD (Neglected Tropical Diseases) Modelling Consortium |
Thomas Lietman, MD |
Neglected Tropical Diseases (NTDs), Epidemiology and Surveillance |
|
|
What is the Appropriate Frequency and Duration of Mass Azithromycin |
Thomas Lietman, MD |
Neglected Tropical Diseases (NTDs), Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
AVENIR: Assessing the impact of azithromycin on child mortality in Niger |
Thomas Lietman, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Pharmacology and Drug Treatment, Pediatrics, Newborn and Infant Health, Health Economics and Effectiveness |
|
|
Mortality Reduction After Oral Azithromycin |
Thomas Lietman, MD |
Infectious Disease, Neglected Tropical Diseases (NTDs), Eye Disease and Blindness, Epidemiology and Surveillance |
|
|
Elimination of Infectious Trachoma from Ethiopia Using Repeated Mass Antibiotic Distributions |
Thomas Lietman, MD |
Infectious Disease, Neglected Tropical Diseases (NTDs), Eye Disease and Blindness |
|
|
Research to Programs for Trachoma Elimination |
Thomas Lietman, MD |
Infectious Disease, Eye Disease and Blindness, Pharmacology and Drug Treatment, Epidemiology and Surveillance |
|
|
Mycotic Ulcer Treatment Trial |
Thomas Lietman, MD |
Infectious Disease, Neglected Tropical Diseases (NTDs), Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
Tools for the Endgame: Accelerating the development and introduction of Dx to Support the London Declaration 2020 goals for Neglected Tropical Diseases (NTDs) |
Thomas Lietman, MD |
Neglected Tropical Diseases (NTDs), Eye Disease and Blindness |
|
|
The Steroids for Corneal Ulcers Trial |
Thomas Lietman, MD |
Infectious Disease, Eye Disease and Blindness, Pharmacology and Drug Treatment |
|
|
Leveraging Core Groups -- A New Way to Protect Against Infectious Trachoma |
Thomas Lietman, MD |
Infectious Disease, Eye Disease and Blindness, Epidemiology and Surveillance |
|
|
Strategies for the Control and Elimination of Blinding Trachoma |
Thomas Lietman, MD |
Infectious Disease, Neglected Tropical Diseases (NTDs), Eye Disease and Blindness |
|
|
TANA II |
Thomas Lietman, MD |
Infectious Disease, Neglected Tropical Diseases (NTDs), Eye Disease and Blindness, Pharmacology and Drug Treatment, Epidemiology and Surveillance |
|
|
A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy with Genotype 1 Chronic Hepatitis C |
Anne Luetkemeyer, MD |
Sexually Transmitted Infections (STIs) |
|
|
Entecavir Intensification for HIV-HBV Coinfected subjects with persistent HBV viremia |
Anne Luetkemeyer, MD |
Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment |
|
|
M14-730 (EXPEDITION-2): A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection |
Anne Luetkemeyer, MD |
Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment |
|
|
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) Coinfected Subjects (GS-US-334-0123) |
Anne Luetkemeyer, MD |
Sexually Transmitted Infections (STIs) |
|
|
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 weeks in Subjects with Chronic HCV and HIV-1 Coinfection |
Anne Luetkemeyer, MD |
Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment |
|
|
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naive Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy |
Anne Luetkemeyer, MD |
Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Subjects with Chronic Hepatitis C |
Anne Luetkemeyer, MD |
Sexually Transmitted Infections (STIs) |
|
|
ASN100-201: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects |
Anne Luetkemeyer, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
GS-US-380-4030: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Co |
Anne Luetkemeyer, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
GS_US_342-1139: Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infecti |
Anne Luetkemeyer, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Subjects with Chronic Hepatitis C |
Anne Luetkemeyer, MD |
Sexually Transmitted Infections (STIs) |
|
|
MK-3682B-037-00A: Phase 3 Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (Grazoprevir/Ruzasvir/Uprifosbuvir) in Participants with Chronic Hepatitis C Virus Genotype 3 Infection |
Anne Luetkemeyer, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Prevention of Emergence of Antibiotic Resistant P. aeruginosa |
|
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
HIV, Hepatitis C, and Pruritus: Data from the Women's Interagency HIV Study |
Toby Maurer, MD |
Infectious Disease, HIV/AIDS, Women's Health |
|
|
Vitamin A Metabolism and Helminth Infection |
Mike McCune, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
Bay Area Hepatitis C Cooperative Research Center |
Mike McCune, MD, PhD |
Infectious Disease, Sexually Transmitted Infections (STIs) |
|
|
The Impact of Tolerance in the Newborn on Lentiviral Infection |
Mike McCune, MD, PhD |
Infectious Disease, Pediatrics |
|
|
In Utero Model to Assess the Fate of Transplanted Human Cells for Translational Research and Pediatric Therapies |
Mike McCune, MD, PhD |
Infectious Disease, Neglected Tropical Diseases (NTDs), Pediatrics |
|
|
Transcriptional Responses of Parasite and Host during Intestinal Colonization and Invasion by Entamoeba histolytica |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Lead Identification to Clinical Candidate Selection: Drugs for Chagas' Disease |
|
Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
Trial of T.cruzi DNA Vaccine in Experimental Model of Disease Challenge Infection |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
Developing a Macrofilaricidal Drug for Onchocerciasis Using Anacor's Novel Oxaborole Technology |
|
Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
Trial of T.cruzi DNA Vaccine in Experimental Model of Disease Challenge Infection |
|
Neglected Tropical Diseases (NTDs) |
|
|
Student and Postdoctoral Collaborations Travel Award |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Residencies, Fellowships, and Postdoctoral Training |
|
|
K777 for the Treatment of Chagas' Disease, IND-enabling Studies and IND Submission |
|
Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
Schistosome Research |
|
Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
Targeting Cysteine Proteases--Antiparasitic Chemotherapy |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Optimization of Cysteine Protease Inhibitors Targeting Trypanosoma Brucei |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Novel Therapeutics for Class B Protozoa |
|
Neglected Tropical Diseases (NTDs) |
|
|
Broad Spectrum Antivirals Targeting Envelope Proteolysis and Viral Uncoating |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
Trypanosome Drug Development Consortium |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
High Throughput Assay for Screening Compounds Against T. Brucei |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Kinetoplastid Drug Development: Strengthening the Preclinical Pipeline |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
Harvesting of S. Mansoni schistosoma eggs |
|
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Host Protein Degradation by Schistosome Parasites |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Identification and Validation of Targets of Phenotypic High Throughput Screening |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
Broad-UCSF Visceral Leishmania Screening Collaboration |
|
Neglected Tropical Diseases (NTDs) |
|
|
Prevalence of baseline and longitudinal heteroresistant M. tuberculosis and association with patient-important outcomes |
John Metcalfe, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Tuberculosis |
|
|
Novel methods for monitoring long-term drug exposure and resistance amplification during treatment of multidrug resistant tuberculosis |
John Metcalfe, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Tuberculosis, Drug and Diagnostics Development |
|
|
Novel methods of pharmacologic monitoring for multidrug resistant tuberculosis treatment in the setting of HIV infection |
John Metcalfe, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Tuberculosis |
|
|
Deep Sequencing Clinical Analysis Tool for Infectious Disease |
|
Infectious Disease, Drug and Diagnostics Development |
|
|
Natural History of HPV Infection to Neoplasia |
Anna-Barbara Moscicki, MD |
Infectious Disease |
|
|
Sangre Segura: An Epidemiological Study of Blood Transfusion Safety in the Mexico-U.S. Border Region |
Edward Murphy, MD, MPH |
Infectious Disease, Transfusion Medicine, Health Systems Strengthening, Risk Reduction and Prevention |
|
|
Natural History of Acute and Chronic HCV in Blood Donors |
Edward Murphy, MD, MPH |
Infectious Disease, Transfusion Medicine |
|
|
Master Agreement: Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) - International Sites |
Edward Murphy, MD, MPH |
HIV/AIDS, Transfusion Medicine, Epidemiology and Surveillance, Training and Capacity Building |
|
|
Retrovirus Epidemiology Donor Study (REDS) |
Edward Murphy, MD, MPH |
Infectious Disease, Transfusion Medicine, Health Systems Strengthening, Risk Reduction and Prevention |
|
|
Master Agreement: Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) - Domestic Sites |
Edward Murphy, MD, MPH |
HIV/AIDS, Transfusion Medicine, Epidemiology and Surveillance |
|
|
TO#1: Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) - International Sites |
Edward Murphy, MD, MPH |
Infectious Disease, Transfusion Medicine, Systematic Reviews and Guideline Development, Epidemiology and Surveillance |
|
|
TO#2 Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) - International Sites |
Edward Murphy, MD, MPH |
HIV/AIDS, Transfusion Medicine |
|
|
Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) - Domestic Hub |
Edward Murphy, MD, MPH |
HIV/AIDS, Transfusion Medicine, Epidemiology and Surveillance |
|
|
Health Outcomes in Blood Donors and Recipients |
Edward Murphy, MD, MPH |
Infectious Disease, Transfusion Medicine, Noncommunicable and/or Chronic Disease, Epidemiology and Surveillance, Risk Reduction and Prevention, Training and Capacity Building, Training International Scholars and Clinicians |
|
|
Retrovirus Epidemiology Donor Study-II REDS-II International Component - Blood Center |
Edward Murphy, MD, MPH |
Infectious Disease, Transfusion Medicine, Health Systems Strengthening |
|
|
Retrovirus Epidemiology and Donor Evaluation Study-III (REDS-III) - International Sites |
Edward Murphy, MD, MPH |
HIV/AIDS, Transfusion Medicine, Epidemiology and Surveillance |
|
|
Pathophysiology of HTLV-I and HTLV-II Infection |
Edward Murphy, MD, MPH |
Transfusion Medicine |
|
|
XV International Conference on Human Retrovirology: HTLV and Related Viruses |
Edward Murphy, MD, MPH |
HIV/AIDS, Infectious Disease, Transfusion Medicine |
|
|
Pathophysiology of HTLV-I and HTLV-II Infection |
Edward Murphy, MD, MPH |
Transfusion Medicine |
|
|
XI International Conference on Human Retrovirology: HTLV |
Edward Murphy, MD, MPH |
HIV/AIDS, Transfusion Medicine |
|
|
Clinical Epidemiology of HTLV-I and HTLV-II Infection |
Edward Murphy, MD, MPH |
Transfusion Medicine |
|
|
Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) - Domestic Sites - PHASE 2 |
Edward Murphy, MD, MPH |
Infectious Disease, Transfusion Medicine, Epidemiology and Surveillance |
|
|
Research training in HIV-related transfusion medicine and hematology in South Africa |
Edward Murphy, MD, MPH |
HIV/AIDS, Transfusion Medicine, Health Systems Strengthening, Training and Capacity Building |
|
|
Effects of blood conservation and donor characteristics on transfused patient outcomes in a large community hospital network |
Edward Murphy, MD, MPH |
Transfusion Medicine, Health Systems Strengthening |
|
|
Research Training in International Transfusion Safety |
Edward Murphy, MD, MPH |
Transfusion Medicine, Health Systems Strengthening, Training International Scholars and Clinicians |
|
|
Novel Maltodextrin-Based, Bacterial Targeting Probes for Bioimaging of Viable MTB In Vivo |
Payam Nahid, MD, MPH |
Zoonosis, Emerging Disease, and Drug Resistance, Tuberculosis, Drug and Diagnostics Development |
|
|
Hepatitis C: Studies of Immunity and Pathogenesis |
Kimberly Page, PhD, MPH |
Sexually Transmitted Infections (STIs) |
|
|
HCV Infection and Treatment in Parolees: Feasibility Study |
Kimberly Page, PhD, MPH |
Sexually Transmitted Infections (STIs) |
|
|
Acute Hepatitis C Infection in Young Injectors |
Kimberly Page, PhD, MPH |
Sexually Transmitted Infections (STIs) |
|
|
HCV Prevention and Care Education |
Kimberly Page, PhD, MPH |
Infectious Disease, Sexually Transmitted Infections (STIs), Patient and Peer Education |
|
|
Acute Hepatitis C Infection in Young Injectors |
Kimberly Page, PhD, MPH |
Infectious Disease, Adolescent Health, Substance Abuse |
|
|
Anal Dysplasia SCC Supplement for P30 Cancer Support Grant to Stimulate HIV/AIDS Cancer Research Projects NCI-designated Cancer Centers |
Joel Palefsky, MD |
HIV/AIDS, Infectious Disease, Cancer/Oncology |
|
|
(PQ5) Role of HIV-associated cellular miRNAs in HPV 16-induced pathogenesis |
Joel Palefsky, MD |
Infectious Disease, Sexually Transmitted Infections (STIs), Cancer/Oncology |
|
|
The Microbiome and Anal Cancer Pathogenesis in HIV-infected Men who have Sex with Men |
Joel Palefsky, MD |
Infectious Disease, HIV/AIDS, Cancer/Oncology |
|
|
Epidemiologic Effects of ART on HIV-related Anal Cancer and Anal Dysplasia |
Joel Palefsky, MD |
Infectious Disease, HIV/AIDS, Cancer/Oncology |
|
|
The Impact of Anogenital Human Papillomavirus in the Transmission of HIV in Urban Brazil: Phase II Study |
Joel Palefsky, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Next Generation of HPV and Cervical Cancer Research in HIV+ Women |
Joel Palefsky, MD |
HIV/AIDS, Infectious Disease, Sexually Transmitted Infections (STIs), Cancer/Oncology |
|
|
AMC-103: A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals |
Joel Palefsky, MD |
Infectious Disease, Sexually Transmitted Infections (STIs) |
|
|
Merck Men's Efficacy Study, V501 |
Joel Palefsky, MD |
Infectious Disease |
|
|
Anal Human Papillomavirus (HPV) in Methamphetamine (MA) Using and Non-Using Men Who Have Sex with Men (MSM) in Los Angeles |
Joel Palefsky, MD |
Infectious Disease, Cancer/Oncology, Substance Abuse, Risk Reduction and Prevention |
|
|
GINI: Gardasil Immunogenicity with Needle-free Injection-Safety and Immunogenicity of Gardasil using IM and ID needle-free injection delivery |
Joel Palefsky, MD |
Sexually Transmitted Infections (STIs), Cancer/Oncology |
|
|
Thai Red Cross S&S, HPV TA008 |
Joel Palefsky, MD |
Infectious Disease, Sexually Transmitted Infections (STIs), Cancer/Oncology, Pharmacology and Drug Treatment |
|
|
Thai Red Cross S&S, HN177 |
Joel Palefsky, MD |
Infectious Disease, Sexually Transmitted Infections (STIs), Cancer/Oncology |
|
|
HPV Testing Contract for UPR NIDCR-funded R21, "Detection of HPV infection in the oral cavity of Hispanics with and without periodontal disease" |
Joel Palefsky, MD |
Infectious Disease, Oral Health |
|
|
APTIMA HPV Clinical Study on Anal Specimens from Men Who Have Sex with Men (MSM) |
Joel Palefsky, MD |
Sexually Transmitted Infections (STIs) |
|
|
Anal Cytology/HPV Testing Study |
Joel Palefsky, MD |
Infectious Disease, Cancer/Oncology, Systematic Reviews and Guideline Development |
|
|
Women and Infants Transmission Study - Human Papillomavirus Protocol |
Joel Palefsky, MD |
Infectious Disease, HIV/AIDS, Cancer/Oncology, Women's Health |
|
|
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years |
Joel Palefsky, MD |
Infectious Disease, HIV/AIDS, Cancer/Oncology |
|
|
HPV Cervical Neoplasia in a Long-Term HIV+ Cohort |
Joel Palefsky, MD |
Sexually Transmitted Infections (STIs), Cancer/Oncology, Women's Health |
|
|
Viral Hepatitis C Infection Long-term Cohort Study (V-HICS) |
Marion Peters, MD |
HIV/AIDS, Infectious Disease |
|
|
Impact of HIV PMTCT Interventions on HBV Disease in n HIV/HBV Co-infected Women and their Infants |
Marion Peters, MD |
Sexually Transmitted Infections (STIs), HIV/AIDS, Women's Health |
|
|
Structure-Aided Design of CYP51 Inhibitors for Treatment of Parasitic Infections |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
Structure and Engineering of Natural Product Cytochrome P450 |
|
Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
Epidemiology of infectious disease |
Travis Porco, PhD, MPH |
Infectious Disease, Eye Disease and Blindness, Epidemiology and Surveillance |
|
|
CDC Preparedness and Emergency Response Research Center |
Travis Porco, PhD, MPH |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
RAPID: Understanding and leveraging asymptomatic infections to control Ebola transmission |
Travis Porco, PhD, MPH |
Infectious Disease, Epidemiology and Surveillance |
|
|
Ebola modeling: behavior, asymptomatic infection, and contacts |
Travis Porco, PhD, MPH |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Epidemiology and Surveillance |
|
|
International Clinics on Infectious Disease Dynamics and Data (ICI3D Program) |
Travis Porco, PhD, MPH |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Training International Scholars and Clinicians |
|
|
Expanded Access to MGAWN1 in Subjects with Suspected West Nile Neuroinvasive Disease; Substantial Exposure, or Infection and a Compromised Immune System |
Jeffrey Ralph, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Pharmacology and Drug Treatment |
|
|
Lead Identification to Clinical Candidate Selection: Drugs for Chagas' Disease |
Adam Renslo, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Chemical Methods for Ferrous Iron Targeted Drug Delivery |
Adam Renslo, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Malaria |
|
|
Identification of Novel Small Molecule Therapeutics for Visceral Leishmaniasis |
Adam Renslo, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
Identification of Novel Small Molecule Therapeutics for Visceral Leishmaniasis |
Adam Renslo, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
Identification of Anti-HIV Lead Compounds Targeting |
Adam Renslo, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS |
|
|
Chemical Methods for Ferrous Iron Dependent Drug Delivery |
Adam Renslo, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Chemical Methods for Ferrous Iron Dependent Drug Delivery |
Adam Renslo, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
Iron-Dependent Drug Delivery as a New Paradigm in Anti-Parasitic Chemotherapy and Prophylaxis |
Adam Renslo, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
RNA Interference and High-Content Image Analysis to Discover New Drug Targets to Treat the Tropical Disease Schistosomiasis |
|
Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development |
|
|
Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies |
Philip J. Rosenthal, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Malaria |
|
|
Development and Testing of New Medications for the Treatment of Emerging Infectious Diseases [II] |
Philip J. Rosenthal, MD |
Infectious Disease, Neglected Tropical Diseases (NTDs), Malaria |
|
|
Resistance of Malaria Parasites to Artemisinin-Based Therapies |
Philip J. Rosenthal, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Malaria |
|
|
Development and Testing of New Medications for the Treatment of Emerging Infectious Diseases [I] |
Philip J. Rosenthal, MD |
Infectious Disease, Drug and Diagnostics Development |
|
|
Discovery of benzoxaboroles for the treatment of cryptosporidiosis |
Philip J. Rosenthal, MD |
Infectious Disease, Drug and Diagnostics Development |
|
|
Berkeley's Minority Health/Global Health Training Program |
Philip J. Rosenthal, MD |
Neglected Tropical Diseases (NTDs), HIV/AIDS, Malaria, Residencies, Fellowships, and Postdoctoral Training |
|
|
Translational Studies of Antimalarial Drug Resistance |
Philip J. Rosenthal, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Malaria |
|
|
Fighting emerging antimalarial drug resistance |
Philip J. Rosenthal, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Malaria |
|
|
A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination with Peginterferon alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17 Infected With Genotype 1 Hepatitis C Virus |
|
Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment, Pediatrics |
|
|
YV25718: A phase IIIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, Ro 25-8310) compared to untreated control in children with HBeAg positive chronic hepatitis B |
|
Infectious Disease, Pediatrics |
|
|
Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with Genotype 2 or 3 Chronic HCV Infection |
|
Infectious Disease, Pharmacology and Drug Treatment |
|
|
A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection |
|
Infectious Disease |
|
|
Infectious disease laboratories |
George Rutherford, MD |
Infectious Disease, Tuberculosis |
|
|
International Traineeships in AIDS Prevention Studies (ITAPS) |
George Rutherford, MD |
Infectious Disease, HIV/AIDS, Residencies, Fellowships, and Postdoctoral Training |
|
|
State Sexually Transmitted Disease Collaborative Program |
George Rutherford, MD |
Sexually Transmitted Infections (STIs), Epidemiology and Surveillance, Risk Reduction and Prevention |
|
|
Sexually Transmitted Disease Prevention Projects: Implementation |
George Rutherford, MD |
Sexually Transmitted Infections (STIs), Epidemiology and Surveillance, Risk Reduction and Prevention |
|
|
Global Fund Prospective Country Evaluations |
George Rutherford, MD |
Infectious Disease, Tuberculosis, Malaria, Women's Health, Pediatrics |
|
|
STD Prevention Training Center |
George Rutherford, MD |
Sexually Transmitted Infections (STIs), Residencies, Fellowships, and Postdoctoral Training, UCSF Professional Education |
|
|
Support for Male Circumcision Evaluatation Meeting |
George Rutherford, MD |
Sexually Transmitted Infections (STIs), HIV/AIDS, Risk Reduction and Prevention |
|
|
State Sexually Transmitted Disease Collaborative Program |
George Rutherford, MD |
Sexually Transmitted Infections (STIs) |
|
|
Valley Fever Vaccine Project 2010 |
George Rutherford, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Opportunistic Infection, Occupational and Environmental Disease, Drug and Diagnostics Development |
|
|
Valley Fever Vaccine Project |
George Rutherford, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Opportunistic Infection, Occupational and Environmental Disease, Drug and Diagnostics Development |
|
|
California Department of Public Health (CDPH) Immunization Branch Contract |
George Rutherford, MD |
Infectious Disease, Engagement in Care, Risk Reduction and Prevention |
|
|
Specialized Infectious Disease Control Program |
George Rutherford, MD |
Infectious Disease |
|
|
Specialized Infectious Disease Control Program |
George Rutherford, MD |
Infectious Disease |
|
|
Strategic Information Technical Assistance Consortium |
George Rutherford, MD |
Infectious Disease, Epidemiology and Surveillance |
|
|
Viral & Rickettsial Disease Laboratory (VRDL) Project |
George Rutherford, MD |
Infectious Disease |
|
|
STD and Viral Hepatitis Prevention and Control |
George Rutherford, MD |
Infectious Disease, Sexually Transmitted Infections (STIs) |
|
|
Diagnosis, Prevention, and Management of Cryptococcus Infection (Meningeal and Non-Meningeal) |
George Rutherford, MD |
Infectious Disease, HIV/AIDS, Opportunistic Infection |
|
|
Technical Assistance to CDC-Ukraine, Network ACCESS-Pro and the Ukrainian Public Health Center |
George Rutherford, MD |
HIV/AIDS, Infectious Disease, Transfusion Medicine, Tuberculosis, Health Systems Strengthening, Training and Capacity Building, Training International Scholars and Clinicians |
|
|
Processing Uganda Swabs for Trachoma Alternative Indicators Study |
Julius Schachter, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Eye Disease and Blindness |
|
|
Evaluation of Abbott RealTime CT/NG for the Detection of C. trachomatis & N. gonorrhoeae from the Pharynx, Rectum & Urethra of MSM |
Julius Schachter, PhD |
Sexually Transmitted Infections (STIs) |
|
|
A smartphone-based point-of-care test for detection of Chlamydia trachomatis |
Julius Schachter, PhD |
Sexually Transmitted Infections (STIs), Drug and Diagnostics Development |
|
|
A point of care assay for chlamydia to assure prompt treatment in at risk minorities |
Julius Schachter, PhD |
Infectious Disease, Eye Disease and Blindness, Drug and Diagnostics Development |
|
|
Genetics of Brazilian Populations |
Mark Seielstad, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Transfusion Medicine, Genetics, Epidemiology and Surveillance |
|
|
Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) - Central Laboratory |
Mark Seielstad, PhD |
HIV/AIDS, Infectious Disease, Transfusion Medicine, Epidemiology and Surveillance |
|
|
Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) - Central Laboratory |
Mark Seielstad, PhD |
HIV/AIDS, Transfusion Medicine, Epidemiology and Surveillance |
|
|
Disease susceptibility and global distribution of genetic variation |
Mark Seielstad, PhD |
HIV/AIDS, Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Transfusion Medicine, Genetics, Epidemiology and Surveillance |
|
|
Identifying Variants Casual for Type 2 Diabetes in Major Human Populations |
Mark Seielstad, PhD |
Transfusion Medicine, Diabetes, Epidemiology and Surveillance |
|
|
Genome-Wide Association Study to Examine Genes Associated with An Increased Risk of Febrile Seizure in Children Following Measles-Containing Vaccines |
Mark Seielstad, PhD |
Infectious Disease, Transfusion Medicine, Immunology, Pharmacology and Drug Treatment, Pediatrics, Epidemiology and Surveillance |
|
|
Retrovirus Epidemiology Donor Study-II (REDS-II) Central Laboratory |
Mark Seielstad, PhD |
Infectious Disease, Sexually Transmitted Infections (STIs), Transfusion Medicine, Health Systems Strengthening |
|
|
Metagenomic Contributions to Type 2 Diabetes Among Filipino Populations |
Mark Seielstad, PhD |
Transfusion Medicine, Diabetes, Genetics, Epidemiology and Surveillance |
|
|
Global Fund SR2020 |
Starley Shade, PhD, MPH |
Infectious Disease, Tuberculosis, Malaria |
|
|
In Vivo Drug Interaction Study |
|
Sexually Transmitted Infections (STIs), Family Planning |
|
|
Content from UCSF Physicians for SexReally.com |
J. Joseph Speidel, MD, MPH |
Sexually Transmitted Infections (STIs), HIV/AIDS, Women's Health, Family Planning, Adolescent Health, Patient and Peer Education |
|
|
International Clinical Research Fellowship |
Christopher Stewart, MD |
Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Tuberculosis, Malaria, Cancer/Oncology, Cardiovascular Disease, Chronic Respiratory Disease, Diabetes, Occupational and Environmental Disease, Eye Disease and Blindness, Oral Health, Residencies, Fellowships, and Postdoctoral Training |
|
|
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health |
Phyllis Tien, MD |
Infectious Disease, HIV/AIDS, Residencies, Fellowships, and Postdoctoral Training |
|
|
Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women |
Phyllis Tien, MD |
Infectious Disease, HIV/AIDS, Immunology, Women's Health |
|
|
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health |
Phyllis Tien, MD |
Infectious Disease, HIV/AIDS |
|
|
HIV Transmission Cluster Analysis to Inform Prevention |
Hong-Ha Truong, PhD, MS, MPH |
Infectious Disease, HIV/AIDS, Neurology and Mental Health, Risk Reduction and Prevention |
|
|
Role of HIV in acceleration of HPV malignancy |
Sharof Tugizov, PhD |
HIV/AIDS, Sexually Transmitted Infections (STIs), Cancer/Oncology |
|
|
Microbicide Pregnancy Registry--Microbicide Trials Network |
Juan Vargas, MD |
Sexually Transmitted Infections (STIs), HIV/AIDS, Drug and Diagnostics Development, Women's Health, Family Planning |
|
|
Microbicide Pregnancy Registry-Microbicide Trials Network |
Juan Vargas, MD |
Sexually Transmitted Infections (STIs), HIV/AIDS, Drug and Diagnostics Development, Women's Health |
|
|
Microbicide Pregnancy Registry--Microbicide Trials Network |
Juan Vargas, MD |
Sexually Transmitted Infections (STIs), Drug and Diagnostics Development, Women's Health, Family Planning |
|
|
Translation Regulation in Giardia lamblia |
|
Infectious Disease, Genetics |
|
|
Regulation of the Development of Trypanosoma brucei |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
Regulation of the Development of Trypanosoma brucei |
|
Neglected Tropical Diseases (NTDs) |
|
|
Regulation of the Development of Tryanosoma brucei |
|
Neglected Tropical Diseases (NTDs) |
|
|
Purine Metabolism in Trichomonas Vaginalis |
|
Infectious Disease, Sexually Transmitted Infections (STIs) |
|
|
Fighting Infections through Research, Science and Technology (FIRST) Service Contract |
Jaime Sepulveda, MD, DSc, MPH |
Neglected Tropical Diseases (NTDs), Health Systems Strengthening |
|
|
Fighting Infections through Research, Science and Technology (FIRST) Phase 1 and 2: Creating a Partnership to Fight Neglected Infectious Disease in Mesoamerica |
Jaime Sepulveda, MD, DSc, MPH |
Neglected Tropical Diseases (NTDs), Health Systems Strengthening |
|
|
Auranofin supplies to test as a macrofilaricide for human onchocerciasis |
Jaime Sepulveda, MD, DSc, MPH |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
Naturally acquired immunity to norovirus in a newborn cohort in Peru |
Caryn Bern, MD, MPH |
Zoonosis, Emerging Disease, and Drug Resistance, Newborn and Infant Health |
|
|
Disrupting Vector-Borne Disease Transmission in Complex Urban Environments |
Caryn Bern, MD, MPH |
Neglected Tropical Diseases (NTDs), Epidemiology and Surveillance |
|
|
Predictors of Cardiomyopathy Progression in a Cohort of Bolivian Patients with Chagas Disease |
Caryn Bern, MD, MPH |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Cardiovascular Disease |
|
|
Chagas |
Caryn Bern, MD, MPH |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
Natural History, Immunity, and Transmission Patterns of Sapovirus in a Nicaraguan Birth Cohort |
Caryn Bern, MD, MPH |
Infectious Disease, Epidemiology and Surveillance |
|
|
Visceral leishmaniasis control in India |
Caryn Bern, MD, MPH |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
Naturally acquired immunity to norovirus in a newborn cohort in Peru |
Caryn Bern, MD, MPH |
Infectious Disease, Immunology, Newborn and Infant Health |
|
|
Identifying Community Factors Impacting STIs among Youth in California |
Claire Brindis, DrPH |
Sexually Transmitted Infections (STIs), Adolescent Health |
|
|
Implementation science and reproductive health on sub-Saharan Africa |
Joelle Brown, PhD |
HIV/AIDS, Infectious Disease, Sexually Transmitted Infections (STIs), Women's Health, Labor and Delivery, Family Planning |
|
|
Natural History and Outcomes of Coccidioidomycosis Retrospective Record Review Study |
|
Infectious Disease, Opportunistic Infection, Systematic Reviews and Guideline Development |
|
|
Efficacy and Safety of Eraxis/Ecalta (Anidulafungin) Compared to Cancidas (Caspofungin) in Patients with Candida Deep Tissue Infection: A Phase 4 Study |
|
Infectious Disease, HIV/AIDS, Opportunistic Infection, Pharmacology and Drug Treatment |
|
|
WSA-CS-003: Open Label Study of Isavuconazole in the Treatment of Patients with Aspergillosis and Renal Impairment or of Patients with Invasive Fungal Disease Caused by Rare Molds, Yeasts or Dimorphic Fungi |
|
Infectious Disease, Opportunistic Infection, Pharmacology and Drug Treatment |
|
|
Economic Opportunity for Zimbabwean Adolescent Orphans |
Philip Darney, MD, MS |
Sexually Transmitted Infections (STIs), HIV/AIDS |
|
|
STI Screening as a Combined HIV Prevention Platform for MSM in Peru |
James Dilley, MD |
Sexually Transmitted Infections (STIs), HIV/AIDS, Epidemiology and Surveillance, Implementation and Behavioral Science, Engagement in Care |
|
|
Trainings for HIV and HCV testing and prevention |
James Dilley, MD |
Infectious Disease, HIV/AIDS, Training and Capacity Building |
|
|
Sexually Transmitted Infections Clinical Trials Group (STICTG) |
Linda Giudice, MD, PhD, MSc |
Sexually Transmitted Infections (STIs) |
|
|
The Connie Wofsy Womens' HIV Study |
Ruth Greenblatt, MD |
Infectious Disease, HIV/AIDS, Women's Health |
|
|
Family Services Network - Ryan White HIV/AIDS Program |
|
Infectious Disease, HIV/AIDS, Systematic Reviews and Guideline Development |
|
|
Hepatitis C Co-infection Clinic: A to T (Acute to Transplant) |
|
Sexually Transmitted Infections (STIs), HIV/AIDS |
|
|
VX11-950-115 An Open Label, Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1) |
|
Sexually Transmitted Infections (STIs), HIV/AIDS |
|
|
Treatment of Acute Hepatitis C Virus in HIV Co-Infection |
|
Sexually Transmitted Infections (STIs), HIV/AIDS |
|
|
Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Who Have Chronic HCV-1/HIV-1 Co-Infection and Are Treatment-Naïve for Hepatitis C |
|
Infectious Disease, HIV/AIDS |
|
|
Providers' Perceptions of the Diaphragm in Southern Africa and the United States |
Cynthia Harper, PhD |
Sexually Transmitted Infections (STIs), HIV/AIDS, Women's Health, Training International Scholars and Clinicians, UCSF Professional Education |
|
|
Public Health Research, Epidemiology, and Surveillance for Hemoglobinopathies (PHRESH) Sickle Cell Disease (SCD)/ Thalassemia Case Reporting |
James Huang, MD |
Infectious Disease, Genetics, Health Systems Strengthening, Risk Reduction and Prevention |
|
|
Bartonella: dissecting niche-specific adaptation in a human pathogen |
|
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Genomic and Clinical Correlates of Human Bartonella Quintana Infection |
|
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Hemin Receptor Gene Family of Bartonella quintana |
|
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Bartonella henselae: Mechanisms of Chronic Bloodstream Infection |
|
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Pathogenesis of HIV-Related Bacillary Angiomatosis |
|
HIV/AIDS, Opportunistic Infection, Infectious Disease, Cancer/Oncology |
|
|
Bartonella Virulence Mechanisms in Patients with AIDS |
|
Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS |
|
|
Host-pathogen interactions: Unveiling common mechanisms for rewiring host factors in infectious processes |
Nevan Krogan, PhD, MSc |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Immunology, Genetics |
|
|
HPMI: Host Pathogen Mapping Initiative |
Nevan Krogan, PhD, MSc |
Zoonosis, Emerging Disease, and Drug Resistance, Immunology, Genetics |
|
|
Systems-Based Analysis of Flaviviral Host Restriction |
Nevan Krogan, PhD, MSc |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
An Intervention for Male STD Patients in India / HIV Related |
Christina (Krysia) Lindan, MD, MSc |
Sexually Transmitted Infections (STIs), HIV/AIDS |
|
|
HSV-2 Avidity Testing for Intervention for Male Sexually-Transmitted Disease (STD) Patients in India |
Christina (Krysia) Lindan, MD, MSc |
Sexually Transmitted Infections (STIs), HIV/AIDS |
|
|
Diagnostic Antibody for Type A Botulism |
|
Infectious Disease, Drug and Diagnostics Development |
|
|
A Patient-Centered Intervention to Increase Screening of Hepatitis B and C among Asian Americans |
Tung Nguyen, MD |
Infectious Disease |
|
|
California Emerging Infections Program |
Ina Park, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Epidemiology and Surveillance, Health Systems Strengthening, UCSF Professional Education |
|
|
Updating HCV treatment engagement paradigms for HIV/HCV coinfected patients |
Elise Riley, PhD |
Infectious Disease, HIV/AIDS, Engagement in Care |
|
|
Host-pathogen Interactions during Vertical Transmission of Listeria monocytogenes |
|
Zoonosis, Emerging Disease, and Drug Resistance, Opportunistic Infection, Women's Health, Labor and Delivery, Newborn and Infant Health |
|
|
Optimal MDR treatment in children |
Rada Savic, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Tuberculosis |
|
|
De Facto Monotherapy during Multidrug Tuberculosis Treatment and Emergence of Resistance |
Rada Savic, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Tuberculosis |
|
|
Integrative Pharmacology Approach to Understand Mechanisms of Tuberculosis Drug Resistance |
Rada Savic, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Tuberculosis, Drug and Diagnostics Development |
|
|
Research Training at the Confluence of Infectious and Non-Communicable Disease |
Dean Schillinger, MD |
Infectious Disease, Neglected Tropical Diseases (NTDs), Training International Scholars and Clinicians, Residencies, Fellowships, and Postdoctoral Training |
|
|
Protocol GS-US-334-0139 An Expanded Access Phase 2 Study of Sofosbuvir and Ribavarin with or without Pegylated Interferon for 24 Weeks in Subjects Who Have Undergone Liver Transplantation and Who Have Aggressive Recurrent Hepatitis C Infection |
|
Infectious Disease, Cancer/Oncology |
|
|
Reducing Health Disparities in Unintended Pregnancies Among Hispanic Adolescents Using a Patient-Centered Computer-Based Clinic Intervention |
|
Sexually Transmitted Infections (STIs), Family Planning, Adolescent Health |
|
|
Defining Natural History and Optimal Treatment Outcome for Chronic HBV Infection |
|
Infectious Disease |
|
|
Randomized Controlled Trial of 6% Cellulose Sulfate Gel and the Effect on Vaginal HIV Transmission |
Ariane Van der Straten, PhD, MPH |
Sexually Transmitted Infections (STIs), HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Congenital Syphilis Elimination Cost-Effectiveness Analysis |
James Kahn, MD, MPH |
Sexually Transmitted Infections (STIs), Health Economics and Effectiveness |
|
|
Multimodal Imaging of Antibody-Mediated Therapy for Japanese Encephalitis Virus |
Michael Wilson, MD |
Infectious Disease, Drug and Diagnostics Development |
|
|
A cognitive behavioral and structural HIV prevention intervention for young Ugandan women engaging in high risk sexual behavior |
Rachel King, PhD, MPH |
Sexually Transmitted Infections (STIs), HIV/AIDS, Women's Health, Implementation and Behavioral Science, Risk Reduction and Prevention |
|
|
Epidemiology capacity building |
Nancy Hills, PhD |
HIV/AIDS, Infectious Disease, Epidemiology and Surveillance |
|
|
Prospective Observational Multi-Center Transfusion Study (PROMMTT) |
|
Transfusion Medicine, Trauma and PTSD |
|
|
Age of Blood in Children in Pediatric Intensive Care Units |
|
Transfusion Medicine, Pediatrics |
|
|
Signaling by Cytoplasmic Tyrosine Kinases in Leukocytes |
|
Infectious Disease, Noncommunicable and/or Chronic Disease, Risk Reduction and Prevention |
|
|
Biotest Analysis for HCMV Infection in Placentas |
Lenore Pereira, PhD |
Infectious Disease, Pharmacology and Drug Treatment, Women's Health, Newborn and Infant Health |
|
|
Fetal Zika virus infection: role of the human placenta |
Lenore Pereira, PhD |
Infectious Disease |
|
|
Fetal HCMV Infection: Role of the Human Placenta |
Lenore Pereira, PhD |
Infectious Disease, Women's Health, Newborn and Infant Health |
|
|
Programmable Genetic Memory in Bacteroides: Diagnosis of Diarrheal Disease |
|
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Pediatrics, Newborn and Infant Health |
|
|
Central Nervous System Events in Primary HIV Infection |
|
Infectious Disease, HIV/AIDS, Neurology and Mental Health |
|
|
Investigating fundamental gaps in Valley Fever knowledge |
Anita Sil, MD, PhD |
Infectious Disease, Occupational and Environmental Disease |
|
|
UC Valley Fever Research Initiative |
Anita Sil, MD, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Genetics |
|
|
Gene Circuits that Control Morphology in Histoplasma |
Anita Sil, MD, PhD |
Infectious Disease, Opportunistic Infection |
|
|
Gene circuits that control morphology in Histoplasma |
Anita Sil, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Opportunistic Infection |
|
|
Molecular Dissection of Histoplasma-Induced Host-Cell Death |
Anita Sil, MD, PhD |
Infectious Disease |
|
|
The Incidence of Bacillary Angiomatosis in Uganda |
|
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Opportunistic Infection |
|
|
Series Editor for Disease Control Priorities, third edition (DCP3) |
Dean Jamison, PhD |
Infectious Disease, Health Economics and Effectiveness, Policy and Standards of Care |
|
|
PREDICT-2 |
Dean Jamison, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Risk Reduction and Prevention |
|
|
Novel Therapeutics for Treatment of River Blindness and Lymphatic Filariasis |
Judy Sakanari, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Non-invasive diagnosis of viable adult filarial infections |
Judy Sakanari, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
Janssen/Sakanari - flubendazole study 20150930 |
Judy Sakanari, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
Profiling of Collaborator's Small Molecule Anti-filarials |
Judy Sakanari, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
Drug Resistant Malaria Clinical and Laboratory Studies |
|
Zoonosis, Emerging Disease, and Drug Resistance, Malaria |
|
|
STD Risks and Latino Adolescents' Sexual Networks |
|
Sexually Transmitted Infections (STIs), Adolescent Health |
|
|
HIV Risk Reduction Through HSV-2 Prevention with N-9 |
|
Sexually Transmitted Infections (STIs) |
|
|
Acceptability of Barrier Methods for Disease Prevention |
|
Sexually Transmitted Infections (STIs) |
|
|
San Francisco STDs CRC |
|
Sexually Transmitted Infections (STIs), Adolescent Health |
|
|
Improving Uses of New and Existing Technologies to Reduce Non-viral STIs in Developing Countries |
|
Sexually Transmitted Infections (STIs) |
|
|
A Phase I Safety Trial of the Diaphragm in Zimbabwe |
|
Sexually Transmitted Infections (STIs), HIV/AIDS, Women's Health, Family Planning |
|
|
Acceptability of Diaphragm Use to Prevent STDs/HIV |
|
Sexually Transmitted Infections (STIs), Women's Health |
|
|
C. elegans as a Targeted Molecular Surrogate for Filarid Parasites 2 |
Kaveh Ashrafi, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Trefoil Factor Proteins Modulate Host Immunity against Hookworms |
|
Zoonosis, Emerging Disease, and Drug Resistance, Immunology |
|
|
Trefoil Factors Regulate Th2 Immunity |
|
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Immunology |
|
|
Interaction between Innate and Th2 Lymphocytes in Helminth Immunity |
Jesse Nussbaum, MD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Advancing Broad Spectrum Host-Targeting Antiviral Strategies to the Clinic |
Kevan Shokat, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
The PIP2-Virus Interface and PI 4-Kinase: Novel Biology and Validation Targets |
Kevan Shokat, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Designing Selective Inhibitors of Calcium-Dependent Kinases in Parasites |
Kevan Shokat, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Nanotextured Condoms: Surface Engineering for Better Safe Sex |
|
Sexually Transmitted Infections (STIs) |
|
|
Informing hepatitis C virus elimination strategies with epidemiological data from highest need populations |
Meghan Morris, PhD, MPH |
Infectious Disease, Sexually Transmitted Infections (STIs), Epidemiology and Surveillance |
|
|
The No One Waits (NOW) Study: Acceptability, feasibility, and effectiveness of a community based on-site point-of-diagnosis HCV treatment study |
Meghan Morris, PhD, MPH |
Infectious Disease, Sexually Transmitted Infections (STIs), Pharmacology and Drug Treatment, Epidemiology and Surveillance |
|
|
End HepC SF research to inform elimination |
Meghan Morris, PhD, MPH |
Infectious Disease, Sexually Transmitted Infections (STIs) |
|
|
Understanding the Interpersonal Context of HIV/HCV risk within Injecting Dyads |
Meghan Morris, PhD, MPH |
Infectious Disease, Sexually Transmitted Infections (STIs), HIV/AIDS, Cancer/Oncology |
|
|
Individual, social, and structural factors on disease transmission in marginalized populations |
Meghan Morris, PhD, MPH |
HIV/AIDS, Infectious Disease, Access or Barriers to Care |
|
|
Cambodia Integrated HIV and Drug Prevention Implementation |
Ellen Stein, MPH |
Sexually Transmitted Infections (STIs), HIV/AIDS, Women's Health, Implementation and Behavioral Science, Engagement in Care, Treatment Adherence |
|
|
Evidenced-based guidelines specific to resource challenged settings |
Teresa Bleakly Kortz, MS, MD |
Infectious Disease, Health Systems Strengthening |
|
|
Bubble continuous positive airway pressure in the treatment of severe pediatric pneumonia in Malawi: a cost-effectiveness analysis |
Teresa Bleakly Kortz, MS, MD |
Infectious Disease, Chronic Respiratory Disease, Health Economics and Effectiveness |
|
|
Causes of non-malarial fever in Malawi |
Teresa Bleakly Kortz, MS, MD |
Infectious Disease, Pediatrics |
|
|
The Contribution of Unsafe Blood Transfusion to HIV Transmission in Africa: A Literature Review |
Malika Morar, MS |
Transfusion Medicine, Access or Barriers to Care, Systematic Reviews and Guideline Development, Epidemiology and Surveillance, Health Systems Strengthening, Risk Reduction and Prevention |
|
|
A Multivariate Analysis of Risk Factors to Cervical HPV Infection: An Evaluation of 150 Women under the GINI Study in Bangkok, Thailand |
Sneh Patel, MS |
Infectious Disease, Cancer/Oncology, Pediatrics |
|
|
Analysis of the rapid policy change toward empirical treatment of fever with artemisinin-based combination therapy in Ebola-burdened areas of Liberia |
Matt Susko, MS |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Malaria, Policy and Standards of Care |
|
|
Philippine-UC Collaboratory for Device Innovation (Education/Training Award) |
Michael Harrison, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Malaria, Drug and Diagnostics Development, Genetics, Training International Scholars and Clinicians |
|
|
Identification of Cobra-specific antibodies |
Charles Craik, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Immunology |
|
|
Digital Disease Detection and Molecular Epidemiology of Viral Pathogens in Peru |
|
Infectious Disease, Epidemiology and Surveillance |
|
|
Digital Disease Detection and Molecular Epidemiology of Viral Pathogens in Peru |
|
Infectious Disease, Epidemiology and Surveillance |
|
|
Improving care delivery for people living with HIV, TB and other chronic diseases through diplomacy |
Michael J. Reid, MD |
Infectious Disease, Sexually Transmitted Infections (STIs), HIV/AIDS, Opportunistic Infection, Tuberculosis, Policy and Standards of Care, Systematic Reviews and Guideline Development, Health Systems Strengthening |
|
|
How Zika virus disrupts neuronal cellular architecture |
Jeremy Reiter, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Vulnerable youth, homelessness, and risk behaviors |
Colette L. Auerswald, MD, MS |
HIV/AIDS, Sexually Transmitted Infections (STIs), Access or Barriers to Care, Stigma and Discrimination |
|
|
Outreach-based STI and HIV testing for street youth in San Francisco |
Colette L. Auerswald, MD, MS |
Sexually Transmitted Infections (STIs), HIV/AIDS, Adolescent Health, Stigma and Discrimination, Risk Reduction and Prevention |
|
|
Blood safety standards and lab capacity in low & mid income countries |
Elizabeth Donegan, MD |
HIV/AIDS, Infectious Disease, Transfusion Medicine, Training International Scholars and Clinicians, Distance learning and mentoring |
|
|
HARC Center: HIV Accessory and Regulatory Complexes |
Alan Frankel, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Immunology |
|
|
UCSF RPB Unrestricted Grant Application |
Stephen Mcleod, MD |
Infectious Disease, Eye Disease and Blindness |
|
|
Diagnosis and treatment of infectious keratitis |
Stephen Mcleod, MD |
Infectious Disease, Eye Disease and Blindness |
|
|
Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy & Safety of Pimodivir in Combination With Standard-of-care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection |
Steven Stoltz, MD |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
Natual History of Acute and Chronic HCV in Blood Donors |
Eric Delwart, PhD |
Infectious Disease, Transfusion Medicine, Epidemiology and Surveillance, Health Systems Strengthening |
|
|
Viral metagenomics to discover viruses |
Eric Delwart, PhD |
Transfusion Medicine, Drug and Diagnostics Development, Epidemiology and Surveillance |
|
|
Population Genetics of the PO1 Locus of SIV and HIV-1 |
Eric Delwart, PhD |
HIV/AIDS, Transfusion Medicine, Genetics, Epidemiology and Surveillance |
|
|
Transfusion medicine and Blood safety: Policy, Diagnostics and Standards development |
Mike Busch, MD, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Transfusion Medicine, Policy and Standards of Care, Systematic Reviews and Guideline Development, Health Systems Strengthening |
|
|
International Training in Transfusion Medicine |
Mike Busch, MD, PhD |
Infectious Disease, Transfusion Medicine, Epidemiology and Surveillance, Health Systems Strengthening, Training International Scholars and Clinicians |
|
|
Treating Snake Envenomation in India: A Costing Analysis for the Adoption of a Small Molecule Therapeutic |
Simran Dhanju, MS |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Epidemiology of leishmaniasis and schistosomiasis |
Donald Heyneman, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
The Impact of Hand Hygiene Medical Aid Films on the Healthcare Workers' Hand Hygiene Practices at Ndola Central Hospital, Zambia: a Mixed Methods Study |
Hanna Larson, MS |
Infectious Disease, Pediatrics, Epidemiology and Surveillance, Engagement in Care |
|
|
Transfusion science and HIV, HTLV, and dengue research in Brazil |
Philip Norris, MD |
Infectious Disease, HIV/AIDS, Immunology, Health Systems Strengthening, Risk Reduction and Prevention, Training and Capacity Building |
|
|
Identifying the role of opportunistic pathogens including Giardia, Cryptosporidia, Microsporidia and Mycobacterium avium |
Robert Owen, MD |
Opportunistic Infection, Zoonosis, Emerging Disease, and Drug Resistance, Occupational and Environmental Disease |
|
|
Immunology & epidemiology of intestinal infectious diseases |
Robert Owen, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Immunology, Epidemiology and Surveillance |
|
|
Global gene array, secretome analyses, and HIV infection analyses of foreskin epithelial cells upon exposure to cervicovaginal fluid from healthy vs. women with bacterial vaginosis |
Grace Turyasingura, MSc |
Sexually Transmitted Infections (STIs) |
|
|
Travel Medicine in Global Health |
Mary Wilson, MD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs) |
|
|
Burkitt’s lymphoma and Kaposi’s sarcoma in Uganda |
John Ziegler, MD, MSc |
Infectious Disease, HIV/AIDS |
|
|
Mass Treatment of Soil-Transmitted Helminths as a Platform for National Cooperation and Action in Peru: |
Xochilt Borja, MS |
Zoonosis, Emerging Disease, and Drug Resistance, Health Economics and Effectiveness |
|
|
Snakebite treatment in Nepal |
Tommaso Bulfone, MS |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development |
|
|
The impact of antimalarial resistance on malaria transmission in Uganda |
Melissa Conrad, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Malaria |
|
|
Sustained Strengthening of Public Health Laboratory, Transfusion Services and Health Care Worker Infection Control Practices for Ebola Virus Disease in Liberia |
Kayla Enriquez, MD, MPH |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Transfusion Medicine, Drug and Diagnostics Development, Policy and Standards of Care, Systematic Reviews and Guideline Development, Health Systems Strengthening, Training International Scholars and Clinicians |
|
|
Academic Consortium Combating Ebola in Liberia |
Kayla Enriquez, MD, MPH |
Infectious Disease, Health Systems Strengthening, Training International Scholars and Clinicians |
|
|
he Efficacy of Various Antibiotics at Targeting Wolbachia for the Treatment of Lymphatic Filariasis |
Emma Gunderson, MS |
Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development, Pharmacology and Drug Treatment |
|
|
Real-time projections of Ebola outbreak size and duration with and without vaccine use in Équateur, Democratic Republic of Congo |
Dan Kelly, MD, MPH |
Infectious Disease, Epidemiology and Surveillance, Global Strategic Information |
|
|
Understanding the epidemiology and natural history of unrecognized Ebola virus infection |
Dan Kelly, MD, MPH |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Drug and Diagnostics Development, Epidemiology and Surveillance |
|
|
Identifying Opportunities to Increase Syphilis Partner Services Uptake and Improve Outcome Measures, San Francisco - Phase II |
Kim Koester, PhD |
Sexually Transmitted Infections (STIs), Engagement in Care |
|
|
Expedited Partner Therapy and the HIV Prevention Cascade Among MSM in Peru |
Catherine Oldenburg, ScD, MPH |
Sexually Transmitted Infections (STIs) |
|
|
Tuberculosis guidelines and best practices internationally |
Sarah Royce, MD, MPH |
Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Tuberculosis |
|
|
Effectiveness of Simulation-Based Training to Prevent and Manage Postpartum Hemorrhage in Low and Middle-Income Countries: A Systematic Review and Meta-Analysis |
Ria Saha, MS |
Infectious Disease, Pediatrics |
|
|
Clinical care and medical education |
David Sears, MD |
Infectious Disease, HIV/AIDS, Malaria |
|
|
Bioinformatics pipeline for ultrarapid pathogen identification from next-generation sequencing of clinical samples |
Taylor Sittler, MD |
Infectious Disease, Drug and Diagnostics Development |
|
|
Meeting cholera's challenge to Haiti and the world: a joint statement on cholera prevention and care |
|
Infectious Disease, Health Economics and Effectiveness, Policy and Standards of Care |
|
|
Vertical Transmission of Zika Virus: Histopathological Investigations at the Maternal- Fetal Interface |
Stephanie Valderramos, MD, PhD |
Infectious Disease, Drug and Diagnostics Development, Immunology |
|
|
Vertical Transmission of Zika Virus: Placental Histopathology and Fetal Outcomes |
Stephanie Valderramos, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Neurology and Mental Health, Newborn and Infant Health |
|
|
Community Perceptions of Intestinal Infections in the Sorsogon Province, the Philippines |
Ekaterina Tangog , MS |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Prevalence, incidence and risk factors for genital and rectal C. trachomatis and N. gonorrhoeae infections and antibiotic resistance in Fiji |
Deborah Dean, MD, MPH |
Sexually Transmitted Infections (STIs), Zoonosis, Emerging Disease, and Drug Resistance, Epidemiology and Surveillance |
|
|
Chlamydial sexually transmitted diseases and trachoma |
Deborah Dean, MD, MPH |
Sexually Transmitted Infections (STIs), Zoonosis, Emerging Disease, and Drug Resistance, Eye Disease and Blindness, Drug and Diagnostics Development |
|
|
Incidence, Prevalence and Risk Factors for Sexually Transmitted Infections in Fiji |
Deborah Dean, MD, MPH |
Infectious Disease, Sexually Transmitted Infections (STIs), Drug and Diagnostics Development |
|
|
Trachoma in Southwestern Nepal |
Deborah Dean, MD, MPH |
Infectious Disease, Eye Disease and Blindness |
|
|
Developing and adapting innovative diagnostic assays for low-resource settings |
Dianna Ng, MD |
Infectious Disease, Drug and Diagnostics Development |
|
|
Quantitative bias analysis to adjust for misclassified pediatric diarrhea in a cluster-randomized trial |
Kristen Aiemjoy, MSc |
Neglected Tropical Diseases (NTDs), Pediatrics |
|
|
Quantitative mapping of interactions between dengue virus and its hosts |
|
Zoonosis, Emerging Disease, and Drug Resistance, Immunology |
|
|
Whole Genome Sequence Characterization of Drug Resistant Malarial Strains |
Sumayya Mohammed, MS |
Zoonosis, Emerging Disease, and Drug Resistance, Malaria, Genetics |
|
|
Sepsis and the Developing World: An Assessment of Barriers and Facilitators to Sepsis Care in Tanzania |
Aleksandra Degtyar, MS |
Infectious Disease, Health Systems Strengthening, Risk Reduction and Prevention, Training and Capacity Building, Training International Scholars and Clinicians |
|
|
Attitudes and Perceptions of a Musical Intervention "Iculo Ngenyoka" for Snakebite Awareness in Swaziland: A Qualitative Study |
Liam Erickson, MS |
Zoonosis, Emerging Disease, and Drug Resistance, Patient and Peer Education |
|
|
Drug-Resistant Tuberculosis on the Texas-Mexico Border: Improving the Quality of bi-national TB Projects |
Camila Hurtado, MS |
Zoonosis, Emerging Disease, and Drug Resistance, Tuberculosis |
|
|
Understanding the Effects of Snake Envenomation in Livestock on the Lives of Farmers in the Southern Pacific Region of Costa Rica |
Andrea Nickerson, MS |
Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Prevalence of and Behaviors Associated with Chlamydia Trachomatis Sexually Transmitted Infections among Females in Suva, Fiji |
Ginny Svigals, MS |
Sexually Transmitted Infections (STIs) |
|
|
Infection Control Training Program: Hand Hygiene in Roatán, Honduras |
Alexis Stanley, MS |
Infectious Disease, Risk Reduction and Prevention |
|
|
Interventions to Improve Non-Malarial Fever Diagnosis in Mobile Health Clinics in Mulanje, Malawi |
Fiona Sylvies, MS |
Infectious Disease, Drug and Diagnostics Development |
|
|
Dissecting the effect of paracrine responses to Zika virus on neurodevelopment in the human brain |
Hanna Retallack, AB |
Zoonosis, Emerging Disease, and Drug Resistance, Immunology |
|
|
The impact of vector control interventions on adverse birth outcomes. |
Michelle Roh, MPH |
Zoonosis, Emerging Disease, and Drug Resistance, Malaria, Women's Health, Newborn and Infant Health |
|
|
Building Evidence for Advancing New Treatment For XDR/XDR-TB (BEAT TUBERCULOSIS) Study |
Patrick Phillips, PhD, MS, MA |
Zoonosis, Emerging Disease, and Drug Resistance, Tuberculosis, Pharmacology and Drug Treatment |
|
|
The M-PulSe Study: Detecting Pulmonary Edema in Sepsis with Lung Ultrasonography in Malawi |
Richard J. Wang, MD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance |
|
|
Estimating the burden of arboviruses in Uganda using age-stratified serological data |
Isabel Rodriguez Barraquer, MD, PhD |
Infectious Disease, Zoonosis, Emerging Disease, and Drug Resistance, Epidemiology and Surveillance |
|
|
Epidemiology of vector borne diseases |
Isabel Rodriguez Barraquer, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Epidemiology and Surveillance |
|
|
Evaluation of an African specific Donor Health Questionnaire for HIV screening in Cameroonian blood services |
Claude Tayou-Tagny, MCR/MPH/MS, MD, MSC |
HIV/AIDS, Transfusion Medicine |
|
|
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting with Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever) |
Mohamed Fayed, MD |
Zoonosis, Emerging Disease, and Drug Resistance, Epidemiology and Surveillance |
|
|
Investigating interactions between pesticide exposures and susceptibility to Zika virus infection in the human placenta |
Stephanie Gaw, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Occupational and Environmental Disease, Newborn and Infant Health |
|
|
Review of modeling studies used in WHO guidelines |
Nathan Lo, MD, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Policy and Standards of Care, Systematic Reviews and Guideline Development |
|
|
New Serological Measures of Infectious Disease Transmission Intensity |
Benjamin F. Arnold, PhD |
Zoonosis, Emerging Disease, and Drug Resistance, Neglected Tropical Diseases (NTDs), Drug and Diagnostics Development, Epidemiology and Surveillance |
|
|
Early Life Factors (Before Age 18) and Breast Cancer Risk in Asian-American Women |
Harry Lin, MS |
Infectious Disease, Cancer/Oncology, Adolescent Health |
|
|
Evaluating the Cost-Effectiveness of COVID-19 Screening Strategies in California Workplaces |
Guntas Padda, MS |
Infectious Disease, Health Economics and Effectiveness, Epidemiology and Surveillance |
|
|
Optimal Strategies to screen health care workers for COVID-19 in the US with SARSCoV-2 PCR and IgG antibody assays: A cost-effectiveness analysis |
Sigal Maya, MS |
Infectious Disease, Health Economics and Effectiveness, Epidemiology and Surveillance |
|
|
Pediatric Sepsis Interventions and Mortality in a Tertiary Emergency Medicine Department in Tanzania |
Brooklyn Dominguez, MS |
Infectious Disease, Emergency & acute care, Pediatrics, Newborn and Infant Health |
|
|
Hepatitis C Clearance in HCV, HTLV-I and HIV co-infected Patients in Salvador, Brazil |
Chloe LeMarchand, MS, MD |
HIV/AIDS, Infectious Disease, Epidemiology and Surveillance |
|
|